|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDCA5 |
Gene summary for CDCA5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDCA5 | Gene ID | 113130 |
| Gene name | cell division cycle associated 5 | |
| Gene Alias | SORORIN | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | A0A024R5D6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 113130 | CDCA5 | P2T-E | Human | Esophagus | ESCC | 2.03e-09 | 3.90e-01 | 0.1177 |
| 113130 | CDCA5 | P4T-E | Human | Esophagus | ESCC | 2.10e-11 | 4.07e-01 | 0.1323 |
| 113130 | CDCA5 | P5T-E | Human | Esophagus | ESCC | 1.53e-19 | 4.20e-01 | 0.1327 |
| 113130 | CDCA5 | P10T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.66e-01 | 0.116 |
| 113130 | CDCA5 | P15T-E | Human | Esophagus | ESCC | 1.50e-02 | 2.12e-01 | 0.1149 |
| 113130 | CDCA5 | P16T-E | Human | Esophagus | ESCC | 9.56e-08 | 2.72e-01 | 0.1153 |
| 113130 | CDCA5 | P17T-E | Human | Esophagus | ESCC | 1.41e-03 | 3.41e-01 | 0.1278 |
| 113130 | CDCA5 | P21T-E | Human | Esophagus | ESCC | 9.35e-10 | 3.41e-01 | 0.1617 |
| 113130 | CDCA5 | P24T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.88e-01 | 0.1287 |
| 113130 | CDCA5 | P28T-E | Human | Esophagus | ESCC | 2.86e-20 | 4.53e-01 | 0.1149 |
| 113130 | CDCA5 | P31T-E | Human | Esophagus | ESCC | 9.02e-11 | 3.43e-01 | 0.1251 |
| 113130 | CDCA5 | P32T-E | Human | Esophagus | ESCC | 2.20e-17 | 4.77e-01 | 0.1666 |
| 113130 | CDCA5 | P37T-E | Human | Esophagus | ESCC | 2.31e-04 | 2.21e-01 | 0.1371 |
| 113130 | CDCA5 | P38T-E | Human | Esophagus | ESCC | 9.50e-06 | 3.29e-01 | 0.127 |
| 113130 | CDCA5 | P42T-E | Human | Esophagus | ESCC | 3.92e-05 | 3.55e-01 | 0.1175 |
| 113130 | CDCA5 | P48T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.16e-01 | 0.0959 |
| 113130 | CDCA5 | P52T-E | Human | Esophagus | ESCC | 5.00e-17 | 5.16e-01 | 0.1555 |
| 113130 | CDCA5 | P56T-E | Human | Esophagus | ESCC | 9.88e-07 | 6.69e-01 | 0.1613 |
| 113130 | CDCA5 | P75T-E | Human | Esophagus | ESCC | 2.03e-09 | 3.97e-01 | 0.1125 |
| 113130 | CDCA5 | P76T-E | Human | Esophagus | ESCC | 9.56e-08 | 3.23e-01 | 0.1207 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:005131011 | Esophagus | ESCC | metaphase plate congression | 58/8552 | 65/18723 | 1.81e-13 | 8.63e-12 | 58 |
| GO:000708011 | Esophagus | ESCC | mitotic metaphase plate congression | 47/8552 | 50/18723 | 3.15e-13 | 1.47e-11 | 47 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:005130311 | Esophagus | ESCC | establishment of chromosome localization | 67/8552 | 80/18723 | 1.92e-12 | 8.09e-11 | 67 |
| GO:005000011 | Esophagus | ESCC | chromosome localization | 68/8552 | 82/18723 | 3.37e-12 | 1.32e-10 | 68 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:003450211 | Esophagus | ESCC | protein localization to chromosome | 70/8552 | 92/18723 | 2.54e-09 | 5.64e-08 | 70 |
| GO:004593116 | Esophagus | ESCC | positive regulation of mitotic cell cycle | 83/8552 | 121/18723 | 2.78e-07 | 4.08e-06 | 83 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDCA5 | SNV | Missense_Mutation | novel | c.208N>A | p.Val70Ile | p.V70I | Q96FF9 | protein_coding | tolerated(1) | benign(0) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| CDCA5 | SNV | Missense_Mutation | novel | c.199N>A | p.Ala67Thr | p.A67T | Q96FF9 | protein_coding | tolerated(0.46) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CDCA5 | SNV | Missense_Mutation | c.467N>G | p.Ser156Cys | p.S156C | Q96FF9 | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CDCA5 | SNV | Missense_Mutation | c.377N>T | p.Ser126Phe | p.S126F | Q96FF9 | protein_coding | tolerated(0.35) | benign(0.081) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CDCA5 | SNV | Missense_Mutation | novel | c.347N>A | p.Pro116His | p.P116H | Q96FF9 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CDCA5 | SNV | Missense_Mutation | c.185N>T | p.Arg62Met | p.R62M | Q96FF9 | protein_coding | deleterious(0) | benign(0.125) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDCA5 | SNV | Missense_Mutation | novel | c.639N>T | p.Glu213Asp | p.E213D | Q96FF9 | protein_coding | tolerated(0.28) | benign(0.079) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDCA5 | SNV | Missense_Mutation | c.661A>G | p.Lys221Glu | p.K221E | Q96FF9 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDCA5 | SNV | Missense_Mutation | novel | c.169N>T | p.Pro57Ser | p.P57S | Q96FF9 | protein_coding | tolerated(0.07) | benign(0.186) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDCA5 | SNV | Missense_Mutation | novel | c.39G>T | p.Gln13His | p.Q13H | Q96FF9 | protein_coding | deleterious(0.02) | benign(0.364) | TCGA-DD-AADB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |